STARD3 and gastric cancer: Beyond the co-amplification of StARD3 with HER2 in breast and gastric cancers (Section 4.1), it has yet to be identified if gene mutations or polymorphisms of any of these proteins listed above have functional consequences for LE/Lys-Chol export that may contribute to oncogenic behavior and drug efficacy.